UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of May 2018
COMMISSION
FILE Number.
000-29338
CORREVIO
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CORREVIO
PHARMA CORP. |
| |
(Registrant) |
| |
|
|
| Date: May 17, 2018 |
By: |
/s/
Justin Renz |
| |
|
Name: Justin Renz |
| |
|
Title: Chief Financial Officer |
Exhibit 99.1
Correvio Pharma Corp, Formerly Cardiome Pharma Corp,
Announces Stock Ticker Symbol Change to CORV
Nasdaq: CORV TSX: CORV
VANCOUVER, May 17, 2018 /CNW/ - Correvio Pharma Corp. (Nasdaq:CORV
/ TSX:CORV), formerly Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing
hospital drugs, today announced that Nasdaq and the Toronto Stock Exchange (TSX) have approved changes to the Company's stock ticker
symbols. Effective today, the Company's common shares will commence trading under the trading symbol "CORV" on
both the Nasdaq and TSX. Upon the effective date, the prior trading symbols (Nasdaq:CRME and TSX:COM) will no longer be active.
William Hunter, MD, CEO and President of Correvio, stated,
"Commencement of trading under the new CORV ticker symbol marks the final step in our strategic transaction with Cipher Pharmaceuticals
and our transition to a European and rest of world focused commercial organization. This is an exciting time for the Company
and we believe we are well positioned for meaningful, long-term growth."
About Correvio Pharma Corp.
Correvio Pharma Corp. is a revenue-generating, specialty pharmaceutical
company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a
commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes
brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™
(dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio®
(ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP,
HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute
coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker
used to control rapid heart rate in a number of cardiovascular indications. Correvio's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to deliver Remodulin® (treprostinil) the world's
leading treatment for pulmonary arterial hypertension.
Correvio is traded on the Nasdaq Capital Market (CORV) and
the Toronto Stock Exchange (CORV). For more information, please visit our web site www.correvio.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking statements") that may not be based on historical fact, including
without limitation statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments
to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
A discussion of the risks and uncertainties facing Correvio are discussed in the most recent annual and quarterly reports of our
former parent company Cardiome Pharma Corp., and detailed from time to time in our other filings with the Securities and Exchange
Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. All
of the risks and certainties disclosed in these filings are hereby incorporated by reference in their entirety. While Correvio
makes these forward-looking statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place
undue reliance on any forward-looking statements made in this press release. All forward-looking statements made herein are based
on our current expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent
events or circumstances, except as required by law.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used
under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used
under license.
Trevyent® is a trademark of SteadyMed and used under license.
All other trademarks are the property of their respective owners.
View
original content:http://www.prnewswire.com/news-releases/correvio-pharma-corp-formerly-cardiome-pharma-corp-announces-stock-ticker-symbol-change-to-corv-300650415.html
SOURCE Correvio Pharma Corp
View original content: http://www.newswire.ca/en/releases/archive/May2018/17/c1205.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Correvio Pharma
Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@correvio.com; Argot Partners, Michelle Carroll, 212.600.1902, michelle@argotpartners.com
CO: Correvio Pharma Corp
CNW 11:34e 17-MAY-18
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024
